home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc. From 11/04/21

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics EPS misses by $0.15

Keros Therapeutics (NASDAQ:KROS): Q3 GAAP EPS of -$0.87 misses by $0.15. Cash and cash equivalents of $221.35M. Press Release For further details see: Keros Therapeutics EPS misses by $0.15

KROS - Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...

KROS - Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

KROS - Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting

LEXINGTON, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...
KROS - Atea Pharma, Evolent among weekly healthcare gainers; Omeros, Novavax trail

While the S&P 500 index dropped ~2.2% over the week, its healthcare constituents fell ~3.5%, posting the fourth consecutive weekly loss, as the sector — dragged down by life sciences and services — became the worst performer. Headlining the week was Merck (NYSE:MRK) wit...

KROS - Sonoma Pharmaceuticals, Evelo Biosciences leads healthcare gainers; Altimmune, InMode among major losers

Gainers: Sonoma Pharmaceuticals (NASDAQ:SNOA) +33%, Evelo Biosciences (NASDAQ:EVLO) +12%, ZIVO Bioscience (NASDAQ:ZIVO) +12%, Viridian Therapeutics (NASDAQ:VRDN) +7%, Harpoon Therapeutics (NASDAQ:HARP) +7%. Losers: Altimmune (NASDAQ:ALT) -20%, ...

KROS - SWN, CEI and CAPR among mid-day movers

Gainers: Red Cat (OTCQB:RCAT) +46%. AerSale (NASDAQ:ASLEW) +38%. Keros (NASDAQ:KROS) +28%. Camber Energy (NYSE:CEI) +27%. Puhui Wealth Investment Management (NASDAQ:PHCF) +27%. ENGlobal (NASDAQ:ENG) +25%. Paltalk (NASDAQ:PALT) +25%. Aemetis (NASDAQ:AMTX) +20%. Southwestern (NYSE:SWN) +19%. Ne...
KROS - Cellect Biotechnology, Keros Therapeutics leads healthcare gainers; ASLAN Pharmaceuticals, ZIVO Bioscience among major losers

Gainers: Cellect Biotechnology (NASDAQ:APOP) +24%, Keros Therapeutics (NASDAQ:KROS) +24%, Gossamer Bio (NASDAQ:GOSS) +17%, Seelos Therapeutics (NASDAQ:SEEL) +16%, DiaMedica Therapeutics (NASDAQ:DMAC) +9%. Losers: ASLAN Pharmaceuticals (NASDAQ:ASLN)...

KROS - Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences

LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musc...

KROS - Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...
Previous 10 Next 10